Mylan NV (MYL) Stake Increased by US Bancorp DE

US Bancorp DE lifted its position in shares of Mylan NV (NASDAQ:MYL) by 34.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,772,424 shares of the company’s stock after acquiring an additional 457,197 shares during the period. US Bancorp DE’s holdings in Mylan were worth $50,231,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of MYL. Global Retirement Partners LLC lifted its holdings in shares of Mylan by 107.1% during the 1st quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock worth $27,000 after acquiring an additional 500 shares during the period. Pinnacle Bank lifted its holdings in shares of Mylan by 66.4% during the 1st quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock worth $30,000 after acquiring an additional 423 shares during the period. Mascoma Wealth Management LLC bought a new stake in shares of Mylan during the 1st quarter worth approximately $47,000. Kinneret Advisory LLC bought a new stake in shares of Mylan during the 4th quarter worth approximately $71,000. Finally, First Hawaiian Bank lifted its holdings in shares of Mylan by 560.4% during the 4th quarter. First Hawaiian Bank now owns 2,886 shares of the company’s stock worth $79,000 after acquiring an additional 2,449 shares during the period. 83.69% of the stock is owned by institutional investors.

In other Mylan news, insider Paul Campbell sold 11,533 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $27.50, for a total value of $317,157.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.81% of the stock is currently owned by company insiders.

Several brokerages recently commented on MYL. Zacks Investment Research downgraded shares of Mylan from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. UBS Group cut shares of Mylan from a “buy” rating to a “neutral” rating and decreased their price target for the company from $54.00 to $32.00 in a research report on Wednesday, January 23rd. BidaskClub upgraded shares of Mylan from a “strong sell” rating to a “sell” rating in a research report on Tuesday, April 30th. Morgan Stanley upgraded shares of Mylan from an “equal weight” rating to an “overweight” rating and set a $35.00 price target for the company in a research report on Wednesday, March 6th. They noted that the move was a valuation call. Finally, Wells Fargo & Co cut shares of Mylan from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $33.00 to $22.00 in a research report on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company. Mylan presently has an average rating of “Buy” and a consensus target price of $37.35.

NASDAQ:MYL traded up $0.38 during trading hours on Tuesday, reaching $19.81. The company had a trading volume of 3,416,268 shares, compared to its average volume of 6,225,044. Mylan NV has a twelve month low of $19.14 and a twelve month high of $42.50. The stock has a market capitalization of $10.12 billion, a price-to-earnings ratio of 4.32, a PEG ratio of 1.02 and a beta of 1.44. The company has a current ratio of 1.51, a quick ratio of 0.85 and a debt-to-equity ratio of 1.20.

Mylan (NASDAQ:MYL) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.03. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The firm had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same period last year, the firm earned $0.96 earnings per share. The business’s quarterly revenue was down 7.0% compared to the same quarter last year. Equities analysts predict that Mylan NV will post 4.28 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2019/05/21/mylan-nv-myl-stake-increased-by-us-bancorp-de.html.

About Mylan

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Featured Story: Short Selling Stocks and Day Traders

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit